These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 33892148)

  • 1. The impact of COVID-19 on the cell and gene therapies industry: Disruptions, opportunities, and future prospects.
    Qiu T; Wang Y; Liang S; Han R; Toumi M
    Drug Discov Today; 2021 Oct; 26(10):2269-2281. PubMed ID: 33892148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An industry survey of implementation strategies for clinical supply chain management of cell and gene therapies.
    Myles L; Church TD
    Cytotherapy; 2022 Mar; 24(3):344-355. PubMed ID: 34750073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene and cell therapy in South Africa: Current status and future prospects.
    Ely A; Bloom K; Maepa MB; Mahlangu JN; Pepper MS; Arbuthnot P
    S Afr Med J; 2019 Sep; 109(8b):12-16. PubMed ID: 31662143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decentralised manufacturing of cell and gene therapy products: Learning from other healthcare sectors.
    Harrison RP; Ruck S; Rafiq QA; Medcalf N
    Biotechnol Adv; 2018; 36(2):345-357. PubMed ID: 29278756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene and Cell Therapy: Success Stories and Future Challenges.
    Ylä-Herttuala S
    Mol Ther; 2019 May; 27(5):891-892. PubMed ID: 31010739
    [No Abstract]   [Full Text] [Related]  

  • 6. Moving somatic gene editing to the clinic: routes to market access and reimbursement in Europe.
    Rigter T; Klein D; Weinreich SS; Cornel MC
    Eur J Hum Genet; 2021 Oct; 29(10):1477-1484. PubMed ID: 33850300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decentralized manufacturing of cell and gene therapies: Overcoming challenges and identifying opportunities.
    Harrison RP; Ruck S; Medcalf N; Rafiq QA
    Cytotherapy; 2017 Oct; 19(10):1140-1151. PubMed ID: 28797612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell and gene therapy accessibility.
    Rouce RH; Porteus MH
    Science; 2024 Aug; 385(6708):475. PubMed ID: 39088615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies.
    Coyle D; Durand-Zaleski I; Farrington J; Garrison L; Graf von der Schulenburg JM; Greiner W; Longworth L; Meunier A; Moutié AS; Palmer S; Pemberton-Whiteley Z; Ratcliffe M; Shen J; Sproule D; Zhao K; Shah K
    Eur J Health Econ; 2020 Dec; 21(9):1421-1437. PubMed ID: 32794011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating the Clinical Pipeline of Cell and Gene Therapies and Their Potential Economic Impact on the US Healthcare System.
    Quinn C; Young C; Thomas J; Trusheim M;
    Value Health; 2019 Jun; 22(6):621-626. PubMed ID: 31198178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transitioning from development to commercial: risk-based guidance for critical materials management in cell therapies.
    Scott M; Clarke D; Lipsitz Y; Brandwein H; Allickson J; Alzebdeh D; Aleksic S; Kraft C; Lhu L; Cornetta K
    Cytotherapy; 2020 Nov; 22(11):669-676. PubMed ID: 32713719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Towards a common framework for defining ancillary material quality across the development spectrum.
    Ball O; Zylberberg C
    Cytotherapy; 2019 Dec; 21(12):1234-1245. PubMed ID: 31837736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancing cell and gene therapy manufacture through the application of advanced fluorescent optical sensors (Review).
    Harrison RP; Chauhan VM
    Biointerphases; 2017 Dec; 13(1):01A301. PubMed ID: 29246035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Market Access Challenges and Solutions in Cell and Gene Therapy in The Netherlands.
    Velikanova R; Wolters S; Hofstra HS; Postma MJ; Boersma C
    J Mark Access Health Policy; 2024 Sep; 12(3):181-198. PubMed ID: 39193544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Redefining the role of blood establishments as raw material suppliers, manufacturers, and distributors for new cell therapies: the Blood Systems experience.
    Nizzi F
    Transfusion; 2016 Apr; 56(4):29S-31S. PubMed ID: 27079320
    [No Abstract]   [Full Text] [Related]  

  • 16. Pay-for-performance pricing for a breakthrough heart drug: learnings for cell and gene therapies.
    Malik NN
    Regen Med; 2016 Apr; 11(3):225-7. PubMed ID: 26979621
    [No Abstract]   [Full Text] [Related]  

  • 17. Chimeric antigen receptor-T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods.
    Harrison RP; Zylberberg E; Ellison S; Levine BL
    Cytotherapy; 2019 Feb; 21(2):224-233. PubMed ID: 30770285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Manufacturing models permitting roll out/scale out of clinically led autologous cell therapies: regulatory and scientific challenges for comparability.
    Hourd P; Ginty P; Chandra A; Williams DJ
    Cytotherapy; 2014 Aug; 16(8):1033-47. PubMed ID: 24856894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The time has come of a therapeutic (re)positioning of the ultra-rare diseases].
    Martinat C; Peschanski M
    Med Sci (Paris); 2018 Dec; 34(12):1019-1021. PubMed ID: 30623755
    [No Abstract]   [Full Text] [Related]  

  • 20. Value-based payment and financing for cell and gene therapies: challenges and potential solutions.
    Zhang JX; Shugarman LR
    J Med Econ; 2024; 27(1):678-681. PubMed ID: 38652008
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.